Groprinosin (Inosine Pranobex)

Groprinosin is indicated for several viral and immunodeficiency conditions where modulation of the immune response is desired.

• Treatment of herpes simplex virus infections.
• Management of influenza and other acute respiratory viral infections.
• Adjunct therapy for human papillomavirus (HPV)–related lesions.
• Supportive care in patients with documented immunodeficiency.
• Prophylaxis or adjunctive treatment in certain chronic viral infections (e.g., cytomegalovirus) if clinically appropriate.

The safety profile of Groprinosin includes a range of observed adverse events, most of which are mild, transient, and reversible, while rare serious events have been reported in clinical practice.

Common

• Mild gastrointestinal discomfort (nausea, abdominal pain).
• Transient headache or dizziness.
• Low‑grade fever or flu‑like symptoms.
• Skin rash or mild pruritus.
• Fatigue or mild weakness.
• Insomnia or sleep disturbances.
• Mild elevation of blood pressure.

Serious

• Severe allergic reaction (anaphylaxis, angioedema).
• Hematologic abnormalities (e.g., leukopenia, thrombocytopenia).
• Hepatic enzyme elevation indicating possible liver injury.
• Autoimmune manifestations such as lupus‑like syndrome.
• Cardiovascular events such as arrhythmia or hypotension.
• Renal impairment or acute kidney injury.

When prescribing Groprinosin, clinicians should evaluate patient history and monitor for conditions that may increase the risk of adverse outcomes.

• Assess for known hypersensitivity to inosine pranobex or any excipients.
• Use caution in patients with pre‑existing liver or kidney disease.
• Evaluate immune status before initiating therapy in immunocompromised individuals.
• Consider pregnancy and lactation status; safety data are limited.
• Monitor complete blood count and liver function tests during prolonged treatment.
• Avoid use in patients receiving live vaccines due to potential immune modulation.

Groprinosin may interact with other medicines that affect immune function or share metabolic pathways, potentially altering efficacy or safety.

Avoid

• Concurrent use with immunosuppressive agents such as corticosteroids or calcineurin inhibitors.
• Combination with other antiviral drugs that have overlapping toxicity profiles (e.g., ribavirin).
• Simultaneous administration with live attenuated vaccines.
• Avoid combination with drugs that prolong QT interval, as additive cardiac risk has not been fully evaluated.

Use with caution

• Co‑administration with drugs metabolized by the cytochrome P450 system; monitor plasma levels if clinically relevant.
• Use together with medications that may cause hematologic changes, such as chemotherapy agents.
• Concomitant use with hepatotoxic substances; periodic liver function monitoring is advisable.